BeSt Study: Patient Characteristics

1
(No Transcript)
2
(No Transcript)
3
BeSt Study Patient Characteristics

• Total Population 508
• Female 67
• Male 33
• Age (years) 54
• Duration of symptoms (weeks) 23
• Time diagnosis inclusion (weeks) 2
• DAS 44 4.4
• RF-positive 65
• With erosion 72
• Sharp/vdHeijde score 4

Adapted from Goekoop-Ruiterman et al. Arthritis
Rheum 200552(11)3381-90.
4
Remission Rates for Patients on Initial
Methotrexate/Infliximab Treatment for Early RA
Adapted from 1. Allaart et al. Clin Exp
Rheumatol 200624S77-S82. 2. Van der Kooij et
al. ACR 2006, abstract 658. 3. Van der Kooij et
al. EULAR 2007, abstract THU0215. 4. Klarenbeek
et al. EULAR 2008, abstract THU0162.
5
DAS Results for Initial vs. Delayed Treatment
with IFX MTX at 2-year follow-up
100
Plt0.001
80
56
60
Initial IFX MTX (n120)
Delayed IFX MTX (n86)
P0.005
40
28
25
18
15
20
5
0
failed on IFX MTX
stopped IFX and still DAS lt2.4
stopped IFX and still DAS lt1.6
Delayed Early RA patients started combination
IFX MTX therapy after failing DMARDs
IFX infliximab MTX methotrexate
Adapted from van der Kooij et al. EULAR 2007,
abstract OP0010.
6
Comparative Reduction in CRP Levels
0 to 54 weeks CRP AUC (Plt0.05)
CRP (mg/dL)
Infliximab-free period
Weeks
Adapted from Quinn et al. Arthritis Rheum
20055227-35.
7
BeSt Safety Results
Sequential monotherapy Step-up combination Initial combination with prednisone Initial combination with infliximab
?1 adverse event ( of pts) 43 47 37 39
No. of adverse events 54 57 49 50
Gastrointestinal symptoms 16 15 8 11
Rash/mild dermal or mucosal events 10 12 9 6
Infections 4 7 8 8
Cardiovascular events 2 2 6 2
No. of serious adverse events 8 9 17 6
Adapted from Goedkoop-Ruiterman et al. Arthritis
Rheum 2005523381-90.